Azad, Taha http://orcid.org/0000-0002-9498-0657
Rezaei, Reza
Singaravelu, Ragunath http://orcid.org/0000-0002-2692-3650
Pelin, Adrian
Boulton, Stephen http://orcid.org/0000-0002-2521-2240
Petryk, Julia
Onsu, Kemal Alper
Martin, Nikolas T.
Hoskin, Victoria http://orcid.org/0000-0003-3525-1144
Ghahremani, Mina
Marotel, Marie http://orcid.org/0000-0002-1618-7602
Marius, Ricardo
He, Xiaohong
Crupi, Mathieu J. F.
Hoang, Huy-Dung
Nik-Akhtar, Abolfazl
Ahmadi, Mahsa
Zamani, Nika Kooshki
Golshani, Ashkan
Alain, Tommy http://orcid.org/0000-0002-0396-9138
Greer, Peter
Ardolino, Michele
Dickinson, Bryan C. http://orcid.org/0000-0002-9616-1911
Tai, Lee-Hwa
Ilkow, Carolina S.
Bell, John C. http://orcid.org/0000-0002-9083-357X
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
CCSRI and BioCanRx
Article History
Received: 15 December 2022
Accepted: 11 May 2023
First Online: 26 May 2023
Competing interests
: We declare that J.C.B. has an interest in Turnstone Biologics, which develops the oncolytic Maraba MG1 virus as an OV platform. The remaining authors declare no competing interests.